Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm - A stochastic model of exercise and dietary advice

Preventive Medicine

Volumn 36, Issue 4, 2003, Pages 403-409

  Lindgren, Peter ^a   Fahlstadius, Per ^a   Hellenius, Mai Lis ^b   Jönsson, Bengt ^c   De Faire, Ulf ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Cardiovascular disease; Diet; Economics, Medical; Exercise; Primary prevention

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIETARY INTAKE; EVALUATION; EXERCISE; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LIFESPAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SCREENING; SIMULATION; STOCHASTIC MODEL; SWEDEN;

EID: 0037375922     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-7435(02)00060-9     Document Type: Article

References (29)

1. The National Board of Health and Welfare (Socialstyrelsen). Yearbook of health and medical care 1999 (Sjukvårdsstatistisk årsbok 1999). Stockholm, 1999.
2. Asplund K, Wall S. Vad vet vi omorsaken till hjärt-kärlsjukdom? Stockholm: Socialstyrelsen, 1992.
3. Hellenius M.-L., Rosell M., Sandgren J., de Faire U. High prevalence of overweight and metabolic syndrome among 60 year old women and men in Stockholm, Sweden. XIIth International Symposium on Atheroscloris. 2000;Elsevier, Stockholm, Sweden.
4. Russel L.B., Gold M.R., Siegel J.R., Daniels N., Weinstein M.C. The role of cost-effectiveness analysis in health and medicine. JAMA. 276:1996;1172-1177.
5. Jönsson B., Johannesson M., Kjekshus J., Olsson A.G., Pedersen T.R., Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J. 17:1996;1001-1007.
6. Johannesson M., Jönsson B., Kjekshus J., Olsson A.G., Pedersen T.R., Wedel H. Cost effectiveness of Simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 336:1997;332-336.
7. The National Board of Health Technology Assessment (SBU). Att förebygga sjukdom i hjärta och kärl genom befolkningsinriktade program - en systematisk litteraturöversikt. Stockholm: Statens beredning för utvärdering av medicinsk teknik, 1997.
8. Johannesson M. The cost-effectiveness of hypertension treatment in Sweden. PharmacoEconomics. 7:1995;242-250.
9. Johannesson M. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J. 22:2001;919-925.
10. Hellenius M.L., de Faire U., Berglund B., Hamsten A., Krakau I. Diet and exercise are equally effective in reducing risk for cardiovascular disease. Results of a randomized controlled study in men with slightly to moderately raised cardiovascular risk factors. Atherosclerosis. 103:1993;81-91.
11. Hatziandreu E.I., Koplan J.P., Weinstein M.C., Caspersen C.J., Warner K.E. A cost-effectiveness analysis of exercise as a health promotion activity. Am J Public Health. 78:1988;1417-1421.
12. Lowensteyn I., Coupal L., Zowall H., Grover S.A. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. J Cardpulm Rehabil. 20:2000;147-155.
13. Johannesson M., Borgquist L., Jönsson B., Lindholm L.H. The cost effectiveness of lipid lowering in Swedish primary health care. J Intern Med. 240:1996;23-29.
14. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 16:1997;33-64.
15. Sonnenberg F.A., Beck J.R. Markov models in medical decision making a practical guide . Med Decis Making. 13:1993;322-338.
16. Johannesson M., Hedbrandt J., Jönsson B. A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Med Inf (Lond). 16:1991;355-362.
17. Zethraeus N., Johannesson M., Jönsson B. A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care. 15:1999;352-365.
18. Zethraeus N, Lindgren P, Johnell O, Jönsson B. A computer model to analyse the cost-effectiveness of hormone replacement therapy - a revised version. Stockholm: The Economic Research Institute, Stockholm School of Economics, 2000.
19. Kannel WB, Wolf PA, Garrison RJ. The Framingham study: an epidemiological investigation of cardiovascular disease. Section 37: the probability of developing certain cardiovascular diseases in eight years at specified values of some characteristics. Springfield: U.S. Dept of Commerce National Technical Information Service, 1988.
20. Statistics Sweden. Population statistics 1996 (Befolkningsstatistik 1996). Sveriges Statistiska Databaser, Statistics Sweden 2000.
21. The National Board of Health and Welfare (Socialstyrelsen). Causes of death register 1987-1996 (Dödsorsaksregistret 1987-1996). EpCStat 2000.
22. Kannel WB, Wolf PA, Garrison RJ. The Framingham study: an epidemiological investigation of cardiovascular disease. Section 35: survival following initial cardiovascular events, 30 year follow up. Springfield: U.S. Dept of Commerce National Technical Information Service, 1988.
23. Zethraeus N., Molin T., Henriksson P., Jönsson B. Cost of coronary heart disease and stroke the case of Sweden . J Intern Med. 246:1999;151-159.
24. Ekman M. Two essays in health economics. Consumption and production by age with emphasis on health care expenditures and economic evaluation of beta-blocker therapy in heart failure. Managerial Economics Section & Centre for Health Economics. Stockholm: Stockholm School of Economics, 2001.
25. Zethraeus N, Johannesson M, Jönsson B. A computer model to analyse the cost-effectiveness of hormone replacement therapy. Stockholm: The Economic Research Institute, Stockholm School of Economics, 1998.
26. Lundberg L., Johannesson M., Isacsson D.G.I., Borgquist L. Health-state utilities in a general population in relation to age, gender and socioeconomic factors. Eur Public Health. 9:1999;211-217.
27. The National Board of Health Technology Assessment (SBU). Moderately elevated blood pressure. J Intern Med 1995;238(suppl).
28. Hellenius M.L., Dahlof C., Aberg H., Krakau I., de Faire U. Quality of life is not negatively affected by diet and exercise intervention in healthy men with cardiovascular risk factors. Qual Life Res. 4:1995;13-20.
29. Haq I.U., Ramsay L.E., Yeo W.W., Jackson P.R., Wallis E.J. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart. 81:1999;40-46.